Pharmacogenomics and Clinical Genomics

Pharmacogenomics  is the study of the role of genetics in drug response. Computational advances in Pharmacogenomics has proven to be a blessing in research. A large amount of research in the biomedical sciences regarding Pharmacogenomics as of late stems from combinatorial chemistry,[53] genomic mining, omic technologies and high throughput screening. In order for the field to grow rich knowledge enterprises and business must work more closely together and adopt simulation strategies. Major Universities dealing Pharmacogenomics are:  Harvard University, US, , University of Cambridge, UK, National University of Singapore, Singapore, University of Oxford, UK, Karolinska Institute, Sweden, Monash University, Australia, Imperial College London, UK, University of Tokyo, Japan, University of Melbourne, Australia, University of Michigan, US.

Pharmacogenomics aims to customize health care, with decisions and treatments tailored to each individual patient in every way possible. Genomic testing is still a relatively new development in drug treatment, this field is expanding. Currently, more than 100 drugs have label information regarding pharmacogenomics biomarkers. This information is used to improve the selection and dosage of drugs to treat a wide range of conditions, including cardiovascular disease, lung disease, HIV infection, cancer, arthritis, high cholesterol and depression.

  • Translational Pharmacogenomics
  • Applications of NGS to Pharmacogenomics
  • Nutrigenomics
  • Toxicogenomics
  • Biomarker translation and testing
  • Biological and small molecule therapeutics
  • Molecular-targeted interventions including gene therapy
  • Molecular diagnostics
  • Pharmacogenomics
  • Cancer Pharmacogenomics
  • Pharmacogenitics & Individualized therapy
  • Pharmacogenomics in Clinical Therapeutics

Related Conference of Pharmacogenomics and Clinical Genomics

Pharmacogenomics and Clinical Genomics Conference Speakers